Supernus Pharmaceuticals
🇺🇸United States
- Country
- 🇺🇸United States
- Ownership
- Public
- Established
- 2005-01-01
- Employees
- 652
- Market Cap
- $1.9B
- Website
- http://www.supernus.com
- Introduction
Supernus Pharmaceuticals, Inc. engages in the development and commercialization of products for the treatment of central nervous system diseases. It offers Trokendi XR, Oxtellar XR, APOKYN, XADAGO, and MYOBLOC products. The company was founded by Jack A. Khattar on March 30, 2005, and is headquartered in Rockville, MD.
Safety and Tolerability of OXC XR as Adjunctive Therapy in Subjects With Refractory Partial Epilepsy
- First Posted Date
- 2009-05-25
- Last Posted Date
- 2017-05-31
- Lead Sponsor
- Supernus Pharmaceuticals, Inc.
- Target Recruit Count
- 214
- Registration Number
- NCT00908349
Evaluation of Efficacy and Safety of OXC XR as Adjunctive Therapy for Partial Seizures
Phase 3
Completed
- Conditions
- Epilepsies, Partial
- Interventions
- Drug: PlaceboDrug: 2400mg SPN-804Drug: 1200mg SPN-804
- First Posted Date
- 2008-10-15
- Last Posted Date
- 2014-02-11
- Lead Sponsor
- Supernus Pharmaceuticals, Inc.
- Target Recruit Count
- 366
- Registration Number
- NCT00772603
Phase 2a Study of Safety and Tolerability of SPN-810 in Children With ADHD and Persistent Serious Conduct Problems
Phase 2
Completed
- Conditions
- Attention Deficit Disorder With HyperactivityConduct Disorder
- Interventions
- First Posted Date
- 2008-02-29
- Last Posted Date
- 2013-01-28
- Lead Sponsor
- Supernus Pharmaceuticals, Inc.
- Target Recruit Count
- 78
- Registration Number
- NCT00626236
- Locations
- 🇺🇸
Florida Clinical Research Center, Bradenton, Florida, United States
🇺🇸Sarkis Clinical Trials, Gainesville, Florida, United States
🇺🇸CNS Healthcare, Orlando, Florida, United States
© Copyright 2025. All Rights Reserved by MedPath